‘Pharma Admet Testing Market Worth $11.64bn In 2020’ Says Visiongain Report

16 August 2018
Pharma

Visiongain’s new report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies indicates that the pharma ADMET Testing market will see $11.64bn in spending in 2020.

The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.
The lead analyst of this report said “Revenues for the ADMET Testing market will continue to increase during the 2015-2027 period as drug developers focus on improving candidate selection. The market which was once dominated by in vivo and in vitro tests is steadily giving way to in silico methods as technological advances gain footing.
Growth will be driven by the drug development budget cuts and the push for better candidate selections. With an approximate 90% attrition rate in clinical development, drug developers are more inclined than ever to choose better candidates and avoid losing hundreds of millions of clinical trials.”
The 149-page report contains 100 charts that add visual analysis in order to explain the developing trends within the pharma ADMET Testing market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the pharma ADMET Testing market and its leading submarkets: In Vivo ADMET Testing, In Vitro ADMET Testing and In Silico ADMET Testing.
The 149-page report offers market forecasts for the leading regional and national markets: the US, Germany, France, The UK, Italy, Spain, Japan, China, Brazil, Russia, India, South Korea and RoW.
Moreover, our work discusses the leading companies in the pharma ADMET Testing market. Our study also includes SWOT and STEP analysis of this industry and market.

The report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies report will be of value to anyone who wants to better understand the pharma ADMET Testing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma ADMET Testing market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever